Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients in chronic phase

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian Druker, Moshe Talpaz, Debra Resta et al. · New England Journal of Medicine · 2001 · 5.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia

François Guilhot, Claude Chastang, Mauricette Michallet et al. · New England Journal of Medicine · 1997 · 553 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group [see comments]

Rüdiger Hehlmann, H. Heimpel, Joerg Hasford et al. · Blood · 1994 · 458 citations · Full text

Medicine, Hematology, Oncology +10

UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response

N. C. Allan, P.C.A. Shepherd, S Richards · The Lancet · 1995 · 405 citations · Full text

Life Sciences, Hematology, Oncology +12

Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia

Moshe Talpaz, Hagop M. Kantarjian, Razelle Kurzrock et al. · Annals of Internal Medicine · 1991 · 393 citations

Medicine, Hematology, Pharmacology +17